Increasing options for the treatment of osteoporosis.

From the Endocrine Research Unit, College of Medicine, Mayo Clinic, Rochester, MN.This article (10.1056/NEJMe0905480) was published on August 11, 2009, at
New England Journal of Medicine (Impact Factor: 54.42). 09/2009; 361(8):818-20. DOI: 10.1056/NEJMe0905480
Source: PubMed
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background/Introduction: Osteoporosis results in a significant increase in fractures, leading to morbidity and mortality. Adherence is a concern with commonly used antiresorptive agents, the bisphosphonates. Denosumab, which inhibits bone resorption by a different mechanism and is administered subcutaneously every 6 months, may provide an advantage in decreasing fracture risk in those with osteoporosis.
    Canadian Pharmacists Journal 03/2011; 144(2):72-78.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cell fusion is a fundamental biological event that is essential for the development of multinucleated cells such as osteoclasts. Fusion failure leads to the accumulation of dense bone such as in osteopetrosis, demonstrating the importance of fusion in osteoclast maturity and bone remodeling. In a recent study, we reported that Pin1 plays a role in the regulation of bone formation and Runx2 regulation. In this study, we explored the role of Pin1 in osteoclast formation and bone resorption. Pin1 null mice have low bone mass and increased TRAP staining in histological sections of long bones, compared to Pin1 wild-type mice. In vitro osteoclast forming assays with bone marrow-derived monocyte/macrophage revealed that Pin1-deficient osteoclasts are larger than wild-type osteoclasts and have higher nuclei numbers, indicating greater extent of fusion. Pin1 deficiency also highly enhanced foreign body giant cell formation both in vitro and in vivo. Among the known fusion proteins, only DC-STAMP was significantly increased in Pin1−/− osteoclasts. Immunohistochemistry showed that DC-STAMP expression was also significantly increased in tibial metaphysis of Pin1 KO mice. We found that Pin1 binds and isomerizes DC-STAMP and affects its expression levels and localization at the plasma membrane. Taken together, our data indicate that Pin1 is a determinant of bone mass through the regulation of the osteoclast fusion protein DC-STAMP. The identification of Pin1 as a factor involved in cell fusion contributes to the understanding of osteoclast-associated diseases, including osteoporosis, and opens new avenues for therapeutic targets. © 2014 Wiley Periodicals, Inc.
    Journal of Cellular Physiology 05/2014; · 3.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: γ-tocotrienol (GT3), an analogue of vitamin E, has gained increasing scientific interest recently as it provides significant health benefits. GT3 exerts its biological effects not only by virtue of antioxidant properties but also by inhibiting hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. Studies have reported that the mevalonate pathway is relevant for bone metabolism and HMG-CoA reductase inhibitors can increase bone mass and are useful in osteoporosis therapy. However, whether it is involved in the bone anabolic activity of GT3 is not clear. This study was conducted to investigate the ability of GT3 to protect against ovariectomy-induced bone loss, as well as the correlation between the protections and mevalonate pathway. Results showed that mice supplemented with 100mg/kg emulsified GT3 via subcutaneous injection once per month for three months were significantly protected from ovariectomy-induced bone loss as evaluated by various bone structural parameters, bone metabolic gene expression levels and serum levels of biochemical markers for bone resorption and bone formation. Importantly, the effect of GT3 on preventing against ovariectomy-induced bone loss could be reversed by daily supplementation with mevalonate, indicating that GT3 may via an HMG-CoA reductase-dependent mechanism to protect against ovariectomy-induced bone loss. Our results suggest that GT3 is suitable as dietary supplement and has potential as an alternative drug to treat or prevent osteoporosis.
    Bone 07/2014; · 4.46 Impact Factor